Prestige Consumer Healthcare Inc
NYSE:PBH
Prestige Consumer Healthcare Inc
Cash & Cash Equivalents
Prestige Consumer Healthcare Inc
Cash & Cash Equivalents Peer Comparison
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Prestige Consumer Healthcare Inc
NYSE:PBH
|
Cash & Cash Equivalents
$63.6m
|
CAGR 3-Years
1%
|
CAGR 5-Years
21%
|
CAGR 10-Years
-4%
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash & Cash Equivalents
$7.2B
|
CAGR 3-Years
19%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-10%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash & Cash Equivalents
$9.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
Pfizer Inc
NYSE:PFE
|
Cash & Cash Equivalents
$2.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
8%
|
CAGR 10-Years
0%
|
|
Merck & Co Inc
NYSE:MRK
|
Cash & Cash Equivalents
$5.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-10%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash & Cash Equivalents
$2.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-4%
|
See Also
What is Prestige Consumer Healthcare Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
63.6m
USD
Based on the financial report for Dec 31, 2023, Prestige Consumer Healthcare Inc's Cash & Cash Equivalents amounts to 63.6m USD.
What is Prestige Consumer Healthcare Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-4%
Over the last year, the Cash & Cash Equivalents growth was -26%. The average annual Cash & Cash Equivalents growth rates for Prestige Consumer Healthcare Inc have been 1% over the past three years , 21% over the past five years , and -4% over the past ten years .